ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,737.70
0.38%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Mei Pharma, Inc. (MM) (MSHL)

  7. Mei Pharma, Inc. (MM) (MSHL) Noticias

MSHL

Marshall Edwards (MSHL)

Mei Pharma, Inc. (MM)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MSHL
FechaHoraFuenteTítuloSímboloCompañía
09/07/201213:41Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MSHLMei Pharma, Inc. (MM)
05/07/201215:03Edgar (US Regulatory)Prospectus filed pursuant to Rule 424(b)(3) (424B3)NASDAQ:MSHLMei Pharma, Inc. (MM)
02/07/201214:18Edgar (US Regulatory)Current report filing (8-K)NASDAQ:MSHLMei Pharma, Inc. (MM)
28/06/201208:00PR Newswire (US)Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")NASDAQ:MSHLMei Pharma, Inc. (MM)
04/06/201208:00PR Newswire (US)Marshall Edwards Presents Results From Clinical Trial Of Lead Oncology Drug Candidate ME-143NASDAQ:MSHLMei Pharma, Inc. (MM)
29/05/201208:00PR Newswire (US)Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344NASDAQ:MSHLMei Pharma, Inc. (MM)
25/05/201212:32Edgar (US Regulatory)Amended Statement of Beneficial Ownership (SC 13D/A)NASDAQ:MSHLMei Pharma, Inc. (MM)
15/05/201209:05Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:MSHLMei Pharma, Inc. (MM)
14/05/201208:00PR Newswire (US)Marshall Edwards Completes Rights Offering To StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
08/05/201208:00PR Newswire (US)Marshall Edwards Receives $4 Million Subscription From Novogen In Rights OfferingNASDAQ:MSHLMei Pharma, Inc. (MM)
25/04/201208:00PR Newswire (US)Marshall Edwards Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating CancerNASDAQ:MSHLMei Pharma, Inc. (MM)
10/04/201208:00PR Newswire (US)Marshall Edwards Receives FDA Approval of Investigational New Drug Application for Clinical Testing of Oncology Drug Candidat...NASDAQ:MSHLMei Pharma, Inc. (MM)
03/04/201208:00PR Newswire (US)Marshall Edwards Announces Data from Clinical Trial of ME-143 Selected for Presentation at ASCO Annual MeetingNASDAQ:MSHLMei Pharma, Inc. (MM)
28/03/201208:00PR Newswire (US)Marshall Edwards CEO to Present at Needham Healthcare ConferenceNASDAQ:MSHLMei Pharma, Inc. (MM)
27/03/201208:00PR Newswire (US)Marshall Edwards Receives Notice of Effectiveness for Rights Offering to StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
27/03/201205:02Edgar (US Regulatory)Notice of Effectiveness (EFFECT)NASDAQ:MSHLMei Pharma, Inc. (MM)
20/03/201207:55Edgar (US Regulatory)Securities Registration Statement (S-1/A)NASDAQ:MSHLMei Pharma, Inc. (MM)
19/03/201208:00PR Newswire (US)Marshall Edwards Announces Terms for Rights Offering to StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
06/03/201208:00PR Newswire (US)Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344NASDAQ:MSHLMei Pharma, Inc. (MM)
29/02/201208:00PR Newswire (US)Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock ConferenceNASDAQ:MSHLMei Pharma, Inc. (MM)
21/02/201208:00PR Newswire (US)Marshall Edwards Announces Rights Offering to StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
21/02/201205:57Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)NASDAQ:MSHLMei Pharma, Inc. (MM)
21/02/201205:11Edgar (US Regulatory)Securities Registration Statement (S-1)NASDAQ:MSHLMei Pharma, Inc. (MM)
14/02/201215:12Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:MSHLMei Pharma, Inc. (MM)
03/01/201208:00PR Newswire (US)Marshall Edwards Issued New Method of Use Patent for Lead Oncology Drug Candidate ME-344NASDAQ:MSHLMei Pharma, Inc. (MM)
29/12/201108:00PR Newswire (US)Marshall Edwards Adds $2 Million in Private PlacementNASDAQ:MSHLMei Pharma, Inc. (MM)
20/12/201108:00PR Newswire (US)Marshall Edwards Awarded Key Patent For Compositions Of Lead Oncology Drug CandidatesNASDAQ:MSHLMei Pharma, Inc. (MM)
22/11/201108:00PR Newswire (US)Marshall Edwards to Host Annual Meeting of StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
10/11/201108:00PR Newswire (US)Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare ConferenceNASDAQ:MSHLMei Pharma, Inc. (MM)
28/10/201110:44Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:MSHLMei Pharma, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:MSHL

Su Consulta Reciente

USOTC
LNDKS
Landa App (GM)
NYSE
RNF
EU
FR00140083O8
France Emprunt DEtat Oat...
USOTC
OGSAS
Otis Gallery (GM)
ASX
NML
Navarre Minerals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados